arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Phathom Pharmaceuticals, Inc.

PHAT
$8.56 ▲ +0.17 (+2.03%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
35 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
54
Health
Fair
Neutral
auto_awesome

Analytical Summary

Phathom Pharmaceuticals, Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $716.9M
Dividend Yield
Revenue Growth 88.0%
Op. Margin -5.3%
ROIC 1.7%
FCF / Share $-0.02
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.48
info Valuation on last close. End-of-day price, Aug 7, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$74.27M
↑ +88.0%
Net Income Profit after all expenses
$-30.37M
↑ +67.8%
Operating Margin Operating profit as % of sales
-5.3%
↑ +79.9% 2th
FCF / Share Free cash flow per share
$-0.02
↑ +87.7%
Long-Term Debt Long-term obligations
$164.59M
↑ +0.6%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
2
Returns
97
Financial Health
66
Cash Quality
51

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 35 quarters